Related Experiment Video

Updated: May 24, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis

Zhao Wang1, Jianjun Chen, Jin Wang

  • 1Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 847 Monroe Ave., Memphis, Tennessee 38163, USA.

Pharmaceutical Research
|March 14, 2012
PubMed
Abstract

Insights

This study shows that 2-aryl-4-benzoyl-imidazoles (ABIs) overcome multidrug resistance in melanoma cells and inhibit tumor growth and metastasis. These antimitotic compounds show promise for melanoma treatment.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • Identifying novel compounds that overcome MDR is crucial for improving treatment outcomes.

Purpose of the Study:

  • To evaluate the ability of 2-aryl-4-benzoyl-imidazoles (ABIs) to overcome MDR.
  • To determine the cellular target of ABIs.
  • To assess the in vivo antimelanoma efficacy of ABIs.

Main Methods:

  • Assessed ABI MDR-overcoming ability using MDR cell lines overexpressing resistance proteins.
  • Determined ABI cellular target via cell cycle analysis, molecular modeling, and microtubule imaging.
  • Evaluated in vivo antitumor activity and lung metastasis inhibition in melanoma xenograft and metastasis models.

Main Results:

  • ABIs demonstrated similar potency in MDR cells compared to parent cells.
  • ABIs were identified to target tubulin at the colchicine binding site.
  • ABI-288 significantly inhibited melanoma tumor growth (69%) and ABI-274 showed superior lung metastasis inhibition compared to dacarbazine.

Conclusions:

  • 2-aryl-4-benzoyl-imidazoles represent a new class of antimitotic compounds.
  • ABIs overcome clinically significant drug resistance mechanisms in vitro.
  • ABIs are effective in inhibiting melanoma lung metastasis in vivo, warranting further development.

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...